Global Prostate Cancer Drugs Market Report 2020 - ResearchAndMarkets.com

DUBLIN--()--The "Prostate Cancer Drugs Global Market Report 2020" report has been added to ResearchAndMarkets.com's offering.

The global prostate cancer drugs market was valued at about $7.6 billion in 2018 and is expected to grow to $10.38 billion at a CAGR of 8.1% through 2022.

The prostate cancer drugs market consists of sales of various drugs used for the prevention and treatment of prostate cancer. Prostate cancer is one of the most common types of cancer caused due to uncontrollable development of cells in the prostate gland in men that produces the seminal fluid that nourishes and transports sperm. Some of the possible treatments for prostate cancer include hormonal therapy, chemotherapy, immunotherapy and targeted therapy.

North America was the largest region in the prostate cancer drugs market in 2016. This region is expected to remain the largest during the next five years. The prostate cancer drugs market in Asia Pacific is forecasted to register the highest CAGR during 2018-2023.

The increasing male geriatric population is a major driver for the prostate cancer drugs market. Prostate cancer is one of the most common types of cancer in men aged above 60. According to the United Nations (UN), there were around 962 million people aged 60 or above globally, accounting for 13% of the global population in 2017. The population aged 60 or above is also growing at a rate of around 3% per year. The American Cancer Society's statistics for prostate cancer in the USA states that about 6 prostate cancer cases in 10 are diagnosed in men aged 65 or above, and it is rare for men aged less than 40.

Recurrent/non-responsive prostate cancer is major restraint for the growth of the prostate cancer drugs market. This is because recurrent/non-responsive prostate cancer cells lead to recurrence or spread of the cancer after an initial treatment. Prostate cancer can recur locally in the tissue next to the prostate, the surrounding lymph nodes in the pelvis or lymph nodes outside this area, tissues next to the prostate (such as the muscles that help control urination, the rectum, or the wall of the pelvis). The cancer can also travel through the bloodstream and recur in bones or other organs. According to the American Society of Clinical Oncology (ASCO), around 50% to 95% of men in the US with high-risk prostate cancer experience recurrence after localized treatment.

The use of combination therapy to treat prostate cancer is an emerging trend in the market. This is mainly because in some cases of prostate cancer, monotherapy has not been effective for the patients. In this regard, companies in the prostate cancer drugs market are investing more in combination therapy for the treatment of prostate cancer.

For example, in February 2018, Pfizer announced the results of its Phase 3 PROSPER trial in patients with non-metastatic (M0) Castration-Resistant Prostate Cancer (CRPC), which show that the use of XTANDI (enzalutamide) in combination with androgen deprivation therapy (ADT) significantly reduced the risk of developing metastases or death by 71% compared to using ADT alone. Similarly, other combination therapies such as a combination of radiation therapy and androgen deprivation therapy for men with recurrent prostate cancer, and using chemotherapy drug docetaxel (Taxotere) along with ADT are also being used to treat prostate cancer.

The prostate cancer drugs market in the USA is regulated by the FDA which is responsible for approval of new drugs and lays down regulations related to treatment of prostate cancer. In February 2018, the FDA approved Erleada (apalutamide) for the treatment of prostate cancer that has not spread (non-metastatic), but continues to grow despite treatment with hormone therapy (castration-resistant). This was the first case of FDA-approved treatment for non-metastatic, castration-resistant prostate cancer, and more such approvals are expected to follow in the future. Hence, the regulatory scenario related to prostate cancer drugs will encourage more drug manufacturers to enter the market.

In October 2018, Novartis acquired Endocyte for $2.1 billion. This acquisition will help Novartis to develop expands its radiotherapy capabilities for the treatment of prostate cancer. Endocyte is a biopharmaceutical company involved in developing targeted therapies for the personalized treatment of cancer. It was founded in 1996 and headquartered in Indiana, the USA.

Major players in the market are Astellas Inc., AstraZeneca plc, Johnson & Johnson, Sanofi S.A, Bayer AG

Companies Mentioned

  • Roche
  • Abbott
  • Pfizer
  • Norvaris
  • F. Hoffmann-La Roche AG
  • Tolmar Inc
  • AbbVie
  • Siemens Healthcare GmbH
  • Genomic Health
  • OPKO
  • Siemens Healthcare
  • MDx Health
  • Myriad Genetics
  • Janssen Biotech
  • Clovis Oncology
  • Merck Sharp & Dohme
  • Dendreon
  • Ferring Pharmaceuticals
  • GlaxoSmithKline
  • Ipsen
  • Merck & Co.

For more information about this report visit https://www.researchandmarkets.com/r/yzaky5

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900